Die verborgene Krise der KI
Der Wettlauf um 4,6 Milliarden Pfund kritisches Kupfer!
Anzeige
CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion
20,79 EUR
-0,12 %-0,03
4. Nov, 18:58:04 Uhr,
Lang & Schwarz
Kommentare 95
Summer.76,
11.11.2022 16:09 Uhr
0
https://www.businesswire.com/news/home/20221111005229/en/CareDx-Committed-to-Delivering-Clinical-Innovation-to-the-Transplant-Patient-and-Physician-Community
Summer.76,
03.11.2022 21:42 Uhr
0
CareDx GAAP EPS of -$0.06 beats by $0.33, revenue of $79.4M misses by $3.22M
https://seekingalpha.com/news/3901313-caredx-gaap-eps-of-0_06-beats-0_33-revenue-of-79_4m-misses-3_22m
• CareDx press release (NASDAQ:CDNA): Q3 GAAP EPS of -$0.06 beats by $0.33.
• Revenue of $79.4M (+5.0% Y/Y) misses by $3.22M.
• For the full year 2022, CareDx is revising our revenue expectations to be in the range of $320 million to $325 million due to lower Q3 revenue and a higher than anticipated shift in payer mix to commercial payors.
• Full year consensus revenue estimate is $327.79M.
Summer.76,
03.11.2022 21:07 Uhr
0
CareDx Reports Third Quarter 2022 Results
https://www.benzinga.com/pressreleases/22/11/b29555287/caredx-reports-third-quarter-2022-results
Summer.76,
01.11.2022 12:09 Uhr
0
https://www.businesswire.com/news/home/20221101005639/en/Independent-Longitudinal-Study-Finds-CareDx%E2%80%99s-AlloSure-Detects-Early-Signs-of-Rejection-in-Pediatric-Kidney-Transplant-Patients
abeni,
27.09.2022 13:17 Uhr
0
Transplantationspatienten erleben weniger Schmerzen und weniger unerwünschte Ereignisse mit nicht-invasiven Testlösungen von CareDx
https://www.businesswire.com/news/home/20220927005427/en/Transplant-Patients-Experience-Less-Pain-and-Fewer-Adverse-Events-with-CareDx-Non-Invasive-Testing-Solutions
Summer.76,
04.08.2022 22:34 Uhr
0
CareDx Q2 results miss estimates, co revises FY 2022 revenue guidance
https://seekingalpha.com/news/3867475-caredx-q2-results-miss-estimates-co-revises-fy-2022-revenue-guidance
• CareDx press release (NASDAQ:CDNA): Q2 Non-GAAP EPS of -$0.13 misses by $0.02.
• Revenue of $80.6M (+8.6% Y/Y) misses by $1.25M.
• Sees FY 2022 revenue of $325 million to $335 million vs. previous forecast of $330M to $350M. The consensus revenue estimate is $337.96M.
Summer.76,
04.08.2022 22:06 Uhr
0
CareDx Reports Second Quarter 2022 Results
https://www.businesswire.com/news/home/20220804005967/en/CareDx-Reports-Second-Quarter-2022-Results
Summer.76,
02.08.2022 15:36 Uhr
0
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care
https://www.businesswire.com/news/home/20220802005596/en/CareDx-Launches-Personalized-AlloHome-Patient-Monitoring-Solution-to-Augment-Pre--and-Post-Transplant-Care
AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions
Summer.76,
02.06.2022 19:15 Uhr
0
https://www.businesswire.com/news/home/20220602005408/en/CareDx-Leads-Transplant-Innovation-with-AiKidney-an-AI-Clinical-Decision-Support-Tool-for-Predicting-Allograft-Rejection-Risk
Summer.76,
24.05.2022 16:24 Uhr
0
https://www.globenewswire.com/news-release/2022/05/24/2449070/31386/en/CareDx-Receives-CE-Mark-for-AlloSeq-HCT-for-Use-in-Hematopoietic-Cell-Transplantation.html
Summer.76,
17.05.2022 16:58 Uhr
0
https://www.globenewswire.com/news-release/2022/05/17/2444754/31386/en/In-CareDx-Initiated-IP-Litigation-Against-Natera-Natera-Now-Drops-1-of-2-Patents-Originally-Asserted-Against-CareDx.html
Summer.76,
06.05.2022 5:55 Uhr
0
CareDx Reports First Quarter 2022 Results
https://www.globenewswire.com/news-release/2022/05/05/2437284/31386/en/CareDx-Reports-First-Quarter-2022-Results.html
Summer.76,
05.05.2022 15:19 Uhr
0
https://www.globenewswire.com/news-release/2022/05/05/2436571/31386/en/CareDx-Validates-Clinical-Performance-of-AlloMap-Kidney-to-Comprehensively-Assess-Transplant-Rejection.html
Summer.76,
14.04.2022 19:42 Uhr
0
https://www.globenewswire.com/news-release/2022/04/14/2422640/31386/en/CareDx-Reports-Over-200-000-Heart-Transplant-Patient-Results-Served.html
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States
Summer.76,
11.04.2022 16:12 Uhr
0
https://www.globenewswire.com/news-release/2022/04/11/2419896/31386/en/CareDx-the-Leading-Sponsor-of-UNOS-Transplant-Management-Forum-Demonstrates-the-Value-of-Digital-Solutions-to-Improve-Pre-Transplant-Patient-Referral-and-Waitlisting-Workflow.html
Summer.76,
30.03.2022 17:52 Uhr
0
https://www.globenewswire.com/news-release/2022/03/30/2412689/31386/en/CareDx-Partners-with-the-European-Society-for-Organ-Transplantation-to-Provide-Clinical-Evidence-Supporting-the-Use-of-AlloSeq-cfDNA-with-European-Transplant-Healthcare-Professiona.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Phunware ab 27.02.24 RS | +2,88 % | |
2 | BAYER Hauptdiskussion | -0,35 % | |
3 | APPLE Hauptdiskussion | -0,96 % | |
4 | NVIDIA Hauptdiskussion | -0,89 % | |
5 | PLUG POWER Hauptdiskussion | +19,42 % | |
6 | Lilium Aktie | -12,14 % | |
7 | EVOTEC Hauptdiskussion | +12,95 % | |
8 | Super Micro Computer Hauptdiskussion | +1,11 % | |
9 | BTC/USD Hauptdiskussion | -0,77 % | |
10 | Hyzon Motors Registered (A) Hauptdiskussion | -4,62 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Phunware ab 27.02.24 RS | +2,88 % | |
2 | BAYER Hauptdiskussion | -0,73 % | |
3 | APPLE Hauptdiskussion | -1,01 % | |
4 | NVIDIA Hauptdiskussion | +0,10 % | |
5 | Lilium Aktie | -3,33 % | |
6 | PLUG POWER Hauptdiskussion | +19,26 % | |
7 | EVOTEC Hauptdiskussion | +13,45 % | |
8 | Super Micro Computer Hauptdiskussion | +1,36 % | |
9 | VW Hauptdiskussion | -0,28 % | |
10 | Hyzon Motors Registered (A) Hauptdiskussion | -4,63 % | Alle Diskussionen |